



Medicaid and Health Wave
900 SW Jackson Street
Rm. 900-N
Topeka, KS 66612
Phone: 785-296-3981
Fax: 785-296-4813
www.khpa.ks.gov

Drug Utilization Review Board Meeting
Meeting Agenda, Open Session
October 13, 2010, 10:00 a.m.

Meeting Location

HP Enterprise Services ~ Capital and Cedar Crest Rooms
6700 SW Topeka Blvd, Bldg. 283 J, Topeka, Kansas 66619

Board Members

Michael Burke, M.D, Ph.D.	Dennis Grauer, Ph.D.
John Kollhoff, Pharm.D.	Judy McDaniel Dowd, PA-C
Daniel Sutherland, R.Ph.	Roger Unruh, D.O
Kevin Waite, Pharm.D.	

KHPA Staff

LeAnn Bell, Pharm.D.	Marlene Shellenberger
Shelly Liby	

HP Enterprise Services / HID Staff

Karen Kluczykowski, R.Ph.	Debra Quintanilla, R.N.
Lisa Todd, R.Ph.	Nicole Churchwell, Pharm.D.

- I. Call to Order
- II. Announcements
- III. Health Information Designs, Inc (HID)
 - i. Program Assessment
 - ii. Fiscal Year 2011 Intervention Selection
- IV. Old Business
 - A. Review and Approval of April 14, 2010 Meeting Minutes
 - B. Lidoderm[®] (lidocaine patch)
 - i. Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action
- V. New Business
 - A. Preferred Drug List (PDL) Update

- B. Ophthalmic Antihistamine/Mast Cell Stabilizer Combinations
 - i. PDL Non-Preferred PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- C. Pancreatic Enzyme Replacement Products
 - i. PDL Non-Preferred PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- D. Topical Non-Steroidal Anti-Inflammatory Agents
 - i. PDL Non-Preferred PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- E. Calcium Channel Blocker/Angiotensin II Receptor Blocker Combinations
 - i. PDL Non-Preferred PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- F. Intranasal Antihistamines
 - i. PDL Non-Preferred PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- G. Long-Acting Opioids (Duragesic[®] (fentanyl patch), Exalgo[®] (hydromorphone), Butrans[®] (buprenorphine patch))
 - i. Dose Optimization
 - ii. *Public Comment
 - iii. Board Discussion/Action

- H. Suboxone[®] (buprenorphine/naloxone) & Subutex[®] (buprenorphine)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- I. Soma[®] (carisoprodol)
 - i. Quantity and Days Supply Limit
 - ii. *Public Comment
 - iii. Board Discussion/Action

- J. Nucynta[®] (tapentadol)
 - i. Quantity Limit
 - ii. *Public Comment
 - iii. Board Discussion/Action

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**** This agenda is subject to change.**

- K. Prolia[®] (denosumab)
 - i. Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- L. Botulinum Toxins (Botox[®] (onabotulinumtoxinA), Dysport[®] (abobotulinumtoxinA), Myobloc[®] (rimabotulinumtoxinB))
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- M. Xiaflex[®] (collagenase clostridium histolyticum)
 - i. Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- N. Berinert[®] (C1 esterase inhibitor [human])
 - i. Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- O. Remicade[®] (infliximab)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- P. Enbrel[®] (etanercept)
 - i. Revised Clinical PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

VI. Adjourn

**Lunch will be provided for DUR Board Members
NEXT MEETING: January 12, 2011**

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**** This agenda is subject to change.**